Repare Therapeutics Inc. — Director's Dealing 2021

Jun 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2021-06-14

Reporting Person: Foley Todd (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-14	Common Shares	S	881	$33.09	Disposed	2330102	Indirect
2021-06-16	Common Shares	S	1862	$33.33	Disposed	2328240	Indirect

Footnotes

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

F2: The shares were sold as follows: 852 by MPM BioVentures 2014, L.P. ("BV 2014") and 29 by MPM Asset Management Investors BV2014 LLC ("AM BV2014").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in
this footnote.

F4: The shares are held as follows: 2,121,245 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 73,014 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares were sold as follows: 1,800 by BV 2014 and 62 by AM BV2014.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in
this footnote.

F7: The shares are held as follows: 2,119,445 by BV 2014, 135,843 by BV 2014(B) and 72,952 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.